Of the three predicted miRNAs, MiR-658 is overexpressed in gastric cancer and induces gastric cancer metastasis by activating the PAX3-MET pathway [38], while miR-504 can inhibit cell proliferation and migration in non-small-cell lung cancer [39], oral squamous cell carcinoma [40], liver cancer [41], and overexpression in osteosarcoma [42], and breast cancer [43] to enhance the growth and metastasis of tumors. Here, MET is linked to non-small cell lung carcinoma.